Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy

Research output: Contribution to journalComment/debate

5 Citations (Scopus)

Abstract

Pulmonary toxicity of cancer immunotherapies has emerged as an important clinical event that requires prompt identification and management. Although often referred to as pneumonitis, pulmonary toxicity associated with immunotherapy covers a broad and overlapping spectrum of pulmonary manifestations, and, once suspected, the range of differential diagnoses of infectious and neoplastic processes might make the diagnostic process challenging for physicians. Optimal care can require multidisciplinary effort by pulmonologists, medical oncologists, and radiologists, and awareness of the possibility of treatment-induced pulmonary toxicity by emergency department and primary care physicians. This Viewpoint gives an overview of the diagnosis and management of pulmonary toxicity arising from cancer immunotherapy, including widely used treatments, such as immune checkpoint inhibitors, and emerging therapies, such as chimeric antigen receptor T cells.

Original languageEnglish (US)
Pages (from-to)472-478
Number of pages7
JournalThe Lancet Respiratory Medicine
Volume6
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Immunotherapy
Lung
Neoplasms
Neoplastic Processes
Primary Care Physicians
Emergency Medical Services
T-Cell Antigen Receptor
Hospital Emergency Service
Lung Neoplasms
Pneumonia
Differential Diagnosis
Therapeutics
Physicians

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

@article{df362193e0fb4356a2cfea4ff6f0b2c9,
title = "Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy",
abstract = "Pulmonary toxicity of cancer immunotherapies has emerged as an important clinical event that requires prompt identification and management. Although often referred to as pneumonitis, pulmonary toxicity associated with immunotherapy covers a broad and overlapping spectrum of pulmonary manifestations, and, once suspected, the range of differential diagnoses of infectious and neoplastic processes might make the diagnostic process challenging for physicians. Optimal care can require multidisciplinary effort by pulmonologists, medical oncologists, and radiologists, and awareness of the possibility of treatment-induced pulmonary toxicity by emergency department and primary care physicians. This Viewpoint gives an overview of the diagnosis and management of pulmonary toxicity arising from cancer immunotherapy, including widely used treatments, such as immune checkpoint inhibitors, and emerging therapies, such as chimeric antigen receptor T cells.",
author = "Sawsan Rashdan and Minna, {John D.} and Gerber, {David E.}",
year = "2018",
month = "6",
day = "1",
doi = "10.1016/S2213-2600(18)30172-3",
language = "English (US)",
volume = "6",
pages = "472--478",
journal = "The Lancet Respiratory Medicine",
issn = "2213-2600",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy

AU - Rashdan, Sawsan

AU - Minna, John D.

AU - Gerber, David E.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Pulmonary toxicity of cancer immunotherapies has emerged as an important clinical event that requires prompt identification and management. Although often referred to as pneumonitis, pulmonary toxicity associated with immunotherapy covers a broad and overlapping spectrum of pulmonary manifestations, and, once suspected, the range of differential diagnoses of infectious and neoplastic processes might make the diagnostic process challenging for physicians. Optimal care can require multidisciplinary effort by pulmonologists, medical oncologists, and radiologists, and awareness of the possibility of treatment-induced pulmonary toxicity by emergency department and primary care physicians. This Viewpoint gives an overview of the diagnosis and management of pulmonary toxicity arising from cancer immunotherapy, including widely used treatments, such as immune checkpoint inhibitors, and emerging therapies, such as chimeric antigen receptor T cells.

AB - Pulmonary toxicity of cancer immunotherapies has emerged as an important clinical event that requires prompt identification and management. Although often referred to as pneumonitis, pulmonary toxicity associated with immunotherapy covers a broad and overlapping spectrum of pulmonary manifestations, and, once suspected, the range of differential diagnoses of infectious and neoplastic processes might make the diagnostic process challenging for physicians. Optimal care can require multidisciplinary effort by pulmonologists, medical oncologists, and radiologists, and awareness of the possibility of treatment-induced pulmonary toxicity by emergency department and primary care physicians. This Viewpoint gives an overview of the diagnosis and management of pulmonary toxicity arising from cancer immunotherapy, including widely used treatments, such as immune checkpoint inhibitors, and emerging therapies, such as chimeric antigen receptor T cells.

UR - http://www.scopus.com/inward/record.url?scp=85047431568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047431568&partnerID=8YFLogxK

U2 - 10.1016/S2213-2600(18)30172-3

DO - 10.1016/S2213-2600(18)30172-3

M3 - Comment/debate

VL - 6

SP - 472

EP - 478

JO - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

SN - 2213-2600

IS - 6

ER -